Forest Labs Admits Concealment of data – Congressional Probe Expands Sat, 26 Jun 2004 New York Times business reporter, Barry Meier, reports, “Forest officials had not told a medical journal about a failed unpublished study in 2002 of Celexa use in children and adolescents, before the journal published an article…
To: Thomas Insel MD; Tommy Thompson Re: Published NIMH Prozac Trial Report Concealed Suicide Attempts by Teens ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Tel. 212-595-8974 Fax: 212-595-9086 142 West End Ave. Suite 28P New York, NY 10023 Related Link: NIMH Response to AHRP Letter Board of Directors: Vera Hassner Sharav,…
Recent revelations indicate that pharmaceutical companies have selectively reported partial (favorable) clinical trial results from pediatric antidepressant trials and concealed evidence of harm from physicians, other health care professionals, and the public. It is universally agreed in the literature that failure to disclose all trial results compromises physicians’ ability to provide professional care – thereby increasing the likelihood of causing preventable harm. More generally, failure to disclose trial results in scientific publications taints the scientific literature (by rendering it not credible) and, as New York State Attorney General Elliot Spitzer charged recently, constitutes plain and simple fraud.
NIH Expert on Safe Drug Research Seeks Whistleblower Protection Tue, 14 Dec 2004 In the wake of the Associated Press investigative report about unethical NIH-sponsored AIDS research involving infants and pregranant women Africa, and charges of misconduct by high officials at the National Institutes of Health (NIH), Senate Finance Committee…
